Anemia

Adults with obesity who undergo gastric bypass are five times more likely to develop anemia compared with those receiving nonsurgical obesity care, highlighting the importance of long-term adherence to nutritional supplementation.

After more than 7 hours of discussion, the Cardiovascular and Renal Drugs Advisory Committee of the FDA voted against approval of roxadustat for the treatment of anemia due to chronic kidney disease for patients not on dialysis and on dialysis.

Iron deficiency was associated with all-cause mortality and major adverse cardiovascular events regardless of whether anemia was also present, results of a multinational study of patients with chronic kidney disease showed.

Intravenous ferric carboxymaltose corrected iron deficiency anemia among patients with advanced cirrhosis, according to a late breaking presentation at the International Liver Congress.

Akebia Therapeutics Inc. recently announced the FDA accepted its filing of a new drug application for vadadustat for the treatment of anemia in patients with chronic kidney disease.

An article suggesting thrice weekly doses of cinacalcet could manage certain aspects of bone and mineral metabolism in patients with chronic kidney disease who need treatment with dialysis appeared in Nephrology News and Issues.1

Phase 3 trial results of the anemia drug vadadustat for patients with kidney disease show the drug is efficacious but acknowledge safety issues when used in the non-dialysis patient population.

Sanguina has launched a study to examine how its smartphone app that measures hemoglobin levels, known as AnemoCheck Mobile, can be customized for use by patients with chronic kidney disease-related anemia.

Akebia Therapeutics Inc. has submitted a new drug application to the FDA for vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in both adult patients on dialysis and not on dialysis.

The FDA will hold an advisory meeting to review the new drug application for roxadustat, days ahead of the agency’s planned date for approval of the anemia drug, according to a company press release.